STOCK TITAN

Castle Biosciences (CSTL) CFO reports 4,496-share insider stock sale

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Castle Biosciences' chief financial officer reported an insider stock sale. On 12/11/2025, the officer sold 4,496 shares of common stock at $37.45 per share, leaving 50,326 shares owned directly after the transaction.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Stokes Frank

(Last) (First) (Middle)
C/O CASTLE BIOSCIENCES, INC.
505 S. FRIENDSWOOD DRIVE, SUITE 401

(Street)
FRIENDSWOOD TX 77546

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CASTLE BIOSCIENCES INC [ CSTL ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/11/2025 S 4,496 D $37.45 50,326 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
/s/ Frank Stokes, Attorney-in-fact 12/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Castle Biosciences (CSTL) disclose in this filing?

The filing reports that the chief financial officer sold 4,496 shares of Castle Biosciences common stock at $37.45 per share on 12/11/2025.

Who is the reporting person in the Castle Biosciences (CSTL) Form 4?

The reporting person is an officer of Castle Biosciences, serving as the company’s Chief Financial Officer.

How many Castle Biosciences (CSTL) shares does the CFO own after the reported sale?

After the reported transaction, the chief financial officer beneficially owns 50,326 shares of Castle Biosciences common stock, held as direct ownership.

What type of security was involved in the Castle Biosciences (CSTL) insider sale?

The transaction involved common stock of Castle Biosciences, reported in the non-derivative securities table.

Were any derivative securities reported in this Castle Biosciences (CSTL) Form 4?

The section for derivative securities is included, but this excerpt shows no derivative transactions reported for the period.

Is the Castle Biosciences (CSTL) Form 4 filed by one or multiple reporting persons?

The document indicates that it is a Form filed by one reporting person, not a joint or group filing.

Castle Biosciences

NASDAQ:CSTL

CSTL Rankings

CSTL Latest News

CSTL Latest SEC Filings

CSTL Stock Data

1.16B
27.87M
2.9%
93.07%
5.23%
Diagnostics & Research
Services-medical Laboratories
Link
United States
FRIENDSWOOD